Stallergenes Greer Ltd
http://stallergenesgreer.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Stallergenes Greer Ltd
US FDA Bids Adieu To Allergenic Products Adcomm; Vaccines Panel To Take Over Duties
The effort and expense to maintain the committee, which met only 10 days in the past 15 years, can no longer be justified, the FDA said. The terminated panel’s responsibilities will be integrated into the Vaccines and Related Biological Products Advisory Committee.
Novartis’s Peanut Allergy Setback Perks Up Rivals
Opportunity could knock for the smaller but more specialized players in the peanut allergy space now that Novartis has halted trials of its investigational IgE inhibitor ligelizumab.
Stallergenes Greer Gets Hold Of Nestlé’s Palforzia For Peanuts
Nestlé has finally divested the peanut allergy business acquired in 2019 to much fanfare after the treatment spectacularly failed to live up to its blockbuster potential.
Stallergenes Greer's Delisting To Focus Leadership On Facility Issues
The acquisition of the UK-headquartered leading allergy immunotherapy firm by its private majority shareholder is expected to remove the distraction of stock market listing obligations for management.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Alegro Pharma S.R.L.
- Greer Laboratories, Inc.
- Medic Savoure Limited
- Stallergenes Greer plc
- Stallergenes S.A.
- Stallergenes SAS
- Stallergenes S.A.S.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice